<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661022</url>
  </required_header>
  <id_info>
    <org_study_id>STML-401-0414</org_study_id>
    <nct_id>NCT02661022</nct_id>
  </id_info>
  <brief_title>SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemline Therapeutics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stemline Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In
      Relapsed and Refractory Multiple Myeloma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In
      Relapsed and Refractory Multiple Myeloma.

      This study is a Phase 1/2 multi center, open label study of SL-401 in combination with
      standard doses of Pomalidomide and Dexamethasone. The study will be conducted in 2 Phases:
      Phase 1 is the dose escalation Phase to determine the MTD or maximum tested dose of SL-401 in
      combination with standard doses of Pomalidomide and Dexamethasone. In Phase 1, each evaluated
      SL-401 dose level will incorporate an initial &quot;Run-in Cycle&quot; (i.e. cycle 1) of single agent
      SL-401 in at least 3 patients; following the Run-in Cycle, patients who have not experienced
      a DLT will receive combination SL-401/Pomalidomide and Dexamethasone in cycles 2 and beyond.
      All patients in Phase 2 will initiate therapy with the combination of SL-401/Pomalidomide and
      Dexamethasone at the maximum tested dose established in Phase 1 in the same manner (i.e.
      SL-401 alone in cycle 1 followed by combination of SL-401 and Pomalidomide and Dexamethasone
      in cycles 2 and beyond).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with treatment-related and treatment-emergent adverse events</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SL-401 plasma concentration at multiple time points</measure>
    <time_frame>Up to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SL-401 maximum plasma concentration</measure>
    <time_frame>Up to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>SL-401/Pomalidomide/ Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SL-401 in combination with Pomalidomide and Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SL-401/ Pomalidomide/ Dexamethasone</intervention_name>
    <arm_group_label>SL-401/Pomalidomide/ Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients will be considered for inclusion if they meet all of the following
             criteria. (All necessary baseline studies for determining eligibility must be obtained
             within 21 days prior to enrollment.)

               1. Male or female patient who is at least 18 years of age.

               2. Patient has given voluntary written informed consent before performance of any
                  study-related procedures not part of standard (non-investigational) medical care.

               3. Patient has been previously diagnosed with MM based on standard criteria.

               4. Patient has received:

                    1. At least 2 prior therapies including a proteasome inhibitor (≥ 2 cycles) and
                       lenalidomide (≥ 2 cycles), and

                    2. Has achieved at least stable disease (SD) for ≥ 1 cycle of treatment on ≥ 1
                       prior treatment, and

                    3. Has demonstrated disease progression subsequent to treatment, during or
                       within 90 days following completion of the most recent therapy.

               5. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score
                  ≤ 2.

               6. Patient has measurable disease defined as at least 1 of the following:

                    1. Serum M protein ≥ 0.5 /dL (≥5 g/L)

                    2. Urine M protein ≥ 200 mg/24 hours

                    3. Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L)
                       and an abnormal serum FLC ratio (&lt;0.26 or &gt;1.65)

               7. Clinical Laboratory Inclusion Criteria: The following laboratory results must be
                  met within 14 days (or as stipulated) prior to study drug (treatment)
                  administration:

                    1. Absolute neutrophil count (ANC) ≥ 1000 cells/μl (growth factor cannot be
                       used within the previous 7 days).

                    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×
                       upper limit of normal (ULN).

                    3. Platelet count ≥ 50,000/μl (without platelet transfusion in the previous 7
                       days).

                    4. Total bilirubin ≤ 1.5 mg/dL.

                    5. Serum creatinine ≤ 2.0 mL/dL and creatinine clearance ≥ 40 mL/min
                       (calculated by the Cockcroft-Gault Equation or per 24 hour urine
                       collection).

                    6. Serum albumin ≥ 3.2 g/dL in the absence of receipt of (IV) albumin within
                       the previous 72 hours.

                    7. Serum creatine phosphokinase (CPK) ≤ 2.5 × the ULN.

                    8. Serum calcium (corrected for albumin) level at or below the ULN range
                       (treatment of hypercalcemia is allowed and patient may enroll if
                       hypercalcemia returns to normal range with standard treatment).

               8. Left ventricular ejection fraction (LVEF) ≥ institutional lower limit of normal
                  as measured by multigated acquisition scan (MUGA) scan or 2-dimensional
                  echocardiography (ECHO) within 28 days prior to start of therapy and no
                  clinically significant abnormalities on a 12-lead electrocardiogram (ECG).

               9. Females of childbearing potential (FCBP)* must have a negative serum or urine
                  pregnancy test prior to initiation of the SL-401 Run in Cycle (if required) and
                  repeated with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
                  and again within 24 hours of starting Pomalidomide and must either commit to
                  continued abstinence from heterosexual intercourse or begin 2 acceptable methods
                  of birth control, 1 highly effective method and 1 additional effective method at
                  the same time, at least 28 days before she starts taking Pomalidomide through 30
                  days after the last dose of Pomalidomide and 60 days after the last dose of
                  SL-401. FCBP must also agree to ongoing pregnancy testing during the entire
                  duration of treatment. Men must agree to use a latex or synthetic condom during
                  sexual contact with a FCBP even if they have had a vasectomy from the time of
                  signing the informed consent form through 60 days after the last dose of
                  Pomalidomide or SL-401. These same patients must not donate sperm. All patients
                  must be counseled at a minimum of every 28 days about pregnancy precautions and
                  risks of fetal exposure. All patients enrolled into this study, must agree to be
                  registered in and must comply with all requirements of the Pomalidomide REMS(TM)
                  program.

                    -  An FCBP is a sexually mature female who: 1) has not undergone a hysterectomy
                       or bilateral oophorectomy; or 2) has not been naturally postmenopausal for
                       at least 24 consecutive months (i.e., has had menses at any time in the
                       preceding 24 consecutive months).

        Exclusion Criteria:

        Patients will be ineligible for this study if they meet any 1 of the following criteria:

          1. The patient has an active malignancy and/or cancer history that may confound the
             assessment of the study endpoints. Patients with a past cancer history (within 2 years
             of entry) with substantial potential for recurrence and/or ongoing active malignancy
             must be discussed with the Sponsor before study entry. Patients with the following
             neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ
             (including superficial bladder cancer), cervical intraepithelial neoplasia,
             organ-confined prostate cancer with no evidence of progressive disease.

          2. Prior therapy with SL-401 or received any investigational drug within the prior 30
             days or 5 half-lives of the investigational drug, whichever is longer.

          3. Prior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and
             immunotherapy) within the prior 14 days except for alkylating agents (e.g., melphalan)
             within the prior 28 days.

          4. POM-refractory disease (i.e., non-responsive to prior POM [either as monotherapy or in
             combination] or relapse/progressive disease within 60 days of prior POM (either as
             monotherapy or in combination). Prior POM exposure is permitted, provided the
             patient's MM is not considered POM-refractory as defined above.

          5. Primary refractory MM defined as disease that is non-responsive in patients that have
             never achieved at least stable disease or better with any therapy.

          6. Any &gt; grade 1 (according to the National Cancer Institute [NCI] Common Terminology
             Criteria for Adverse Events [CTCAE], v.4.03) adverse reaction unresolved from previous
             treatments or not readily managed and controlled with supportive care. The presence of
             alopecia of any grade and peripheral neuropathy ≤ grade 2 without pain is allowed.

          7. Previous allogeneic stem cell transplantation with active graft-versus-host-disease,
             or treatment with immunosuppressive therapy in the 2 months prior to study entry.

          8. Daily requirement for corticosteroids &gt;10 mg prednisone daily (or equivalent); inhaled
             corticosteroids are permitted.

          9. Patient is known to be human immunodeficiency virus positive, or have chronic or
             active hepatitis B (core- or surface antigen-positive) or active hepatitis C
             infection.

         10. Clinically significant cardiovascular disease (e.g., uncontrolled or any New York
             Heart Association [NYHA] Class 3 or 4, congestive heart failure, uncontrolled or
             unstable angina, history of myocardial infarction or stroke within 6 months prior to
             study entry, uncontrolled hypertension or clinically significant arrhythmias not
             controlled by medication)

         11. Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive
             pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator
             would put the patient at significant risk for pulmonary complications during the
             study.

         12. Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, disseminated intravascular coagulation, or psychiatric illness/social
             situations that would limit compliance with study requirements.

         13. History of erythema multiforme or severe hypersensitivity to prior Immunomodulatory
             Drugs (IMiDs) such as thalidomide and lenalidomide.

         14. The patient is receiving medications that are strong inhibitors of CYP1A2. Patients
             should have discontinued strong CYP1A2 inhibitors (e.g., ciprofloxacin and
             fluvoxamine) at least 5 half-lives before beginning study drug.

         15. The patient continues to smoke cigarettes, which can induce CYP1A2.

         16. Inability to tolerate thromboprophylaxis.

         17. Pregnant or breast feeding. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shay Shemesh, MS</last_name>
    <phone>646.584.9696</phone>
    <email>Trials@stemline.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myo Htut, MD</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>82405</phone_ext>
      <email>mhtut@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Paba-Prada, MD</last_name>
      <phone>617-632-4061</phone>
      <email>ClaudiaP_Prada@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Scott, MD</last_name>
      <phone>503-494-4606</phone>
      <email>scottem@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013 Mar 1;19(5):985-94. doi: 10.1158/1078-0432.CCR-12-2922. Epub 2012 Dec 5. Review.</citation>
    <PMID>23224402</PMID>
  </reference>
  <reference>
    <citation>Aldinucci D, Olivo K, Lorenzon D, Poletto D, Gloghini A, Carbone A, Pinto A. The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma. 2005 Mar;46(3):303-11. Review.</citation>
    <PMID>15621820</PMID>
  </reference>
  <reference>
    <citation>Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T, Ceolin P, Rossi FM, Gattei V, Carbone A, Pinto A. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol. 2002 Feb;160(2):585-96.</citation>
    <PMID>11839579</PMID>
  </reference>
  <reference>
    <citation>Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem. 2000 Jul-Aug;11(4):564-8.</citation>
    <PMID>10898579</PMID>
  </reference>
  <reference>
    <citation>American Cancer Society. Cancer Facts and Figures 2013. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc- 036845.pdf.</citation>
  </reference>
  <reference>
    <citation>Angelot-Delettre F, Frankel AE, Liu SE et al. The IL-3Rα-Targeted Drug SL-401 Selectively kills Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Cells. ASH 2011, Poster #2588.</citation>
  </reference>
  <reference>
    <citation>Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006 Dec 7;444(7120):756-60. Epub 2006 Oct 18.</citation>
    <PMID>17051156</PMID>
  </reference>
  <reference>
    <citation>Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia. 2003 Jan;17(1):155-9.</citation>
    <PMID>12529673</PMID>
  </reference>
  <reference>
    <citation>Chauhan D, Ray A, Brooks C et al. A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)- Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. J Clin Oncol 2013; 31;(suppl; abstr 8582).</citation>
  </reference>
  <reference>
    <citation>Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 6;16(4):309-23. doi: 10.1016/j.ccr.2009.08.019.</citation>
    <PMID>19800576</PMID>
  </reference>
  <reference>
    <citation>Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA, Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996 Feb 1;87(3):1104-12.</citation>
    <PMID>8562936</PMID>
  </reference>
  <reference>
    <citation>Deng Q, Barbieri JT. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol. 2008;62:271-88. doi: 10.1146/annurev.micro.62.081307.162848. Review.</citation>
    <PMID>18785839</PMID>
  </reference>
  <reference>
    <citation>Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002 Mar 15;62(6):1730-6.</citation>
    <PMID>11912147</PMID>
  </reference>
  <reference>
    <citation>FitzGerald D, Pastan I. Targeted toxin therapy for the treatment of cancer. J Natl Cancer Inst. 1989 Oct 4;81(19):1455-63. Review.</citation>
    <PMID>2550658</PMID>
  </reference>
  <reference>
    <citation>Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, Valent P. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006 Feb;47(2):207-22.</citation>
    <PMID>16321850</PMID>
  </reference>
  <reference>
    <citation>Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000 Apr;14(4):576-85.</citation>
    <PMID>10764142</PMID>
  </reference>
  <reference>
    <citation>Frolova O, Frankel AE, Korchin B et al. IL3R-Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem cells in CML. Blood (ASH Meeting Abstracts) 2010 116: Abstract 3403.</citation>
  </reference>
  <reference>
    <citation>Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 1;104(3):547-54.</citation>
    <PMID>15973664</PMID>
  </reference>
  <reference>
    <citation>Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell Cycle. 2008 Jan 15;7(2):188-93. Epub 2007 Nov 18.</citation>
    <PMID>18256530</PMID>
  </reference>
  <reference>
    <citation>Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006 Sep 21;355(12):1253-61. Review.</citation>
    <PMID>16990388</PMID>
  </reference>
  <reference>
    <citation>Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000 Oct;14(10):1777-84.</citation>
    <PMID>11021753</PMID>
  </reference>
  <reference>
    <citation>Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1;111(5):2516-20. Epub 2007 Nov 1.</citation>
    <PMID>17975015</PMID>
  </reference>
  <reference>
    <citation>Lhermitte L, de Labarthe A, Dupret C, Lapillonne H, Millien C, Landman-Parker J, Hermine O, Baruchel A, Sigaux F, Macintyre E, Asnafi V. Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. Leukemia. 2006 Oct;20(10):1908-10. Epub 2006 Aug 10.</citation>
    <PMID>16900212</PMID>
  </reference>
  <reference>
    <citation>Louie GV, Yang W, Bowman ME, Choe S. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol Cell. 1997 Dec;1(1):67-78.</citation>
    <PMID>9659904</PMID>
  </reference>
  <reference>
    <citation>McCann S, Akilov OE, Geskin L. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma. Clin J Oncol Nurs. 2012 Oct;16(5):E164-72. Review.</citation>
    <PMID>23022942</PMID>
  </reference>
  <reference>
    <citation>Muñoz L, Nomdedéu JF, López O, Carnicer MJ, Bellido M, Aventín A, Brunet S, Sierra J. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001 Dec;86(12):1261-9.</citation>
    <PMID>11726317</PMID>
  </reference>
  <reference>
    <citation>National Cancer Institute-Common Terminology Criteria: Version 4.03 reference, accessible through the NCI website at http://ctep.info.nih.gov/reporting/ctc.html.</citation>
  </reference>
  <reference>
    <citation>Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15;19(2):376-88.</citation>
    <PMID>11208829</PMID>
  </reference>
  <reference>
    <citation>Perentesis JP, Miller SP, Bodley JW. Protein toxin inhibitors of protein synthesis. Biofactors. 1992 Jan;3(3):173-84. Review.</citation>
    <PMID>1599611</PMID>
  </reference>
  <reference>
    <citation>Pomalidomide Perscribing Information. POMPI.001/MG.001 02/13. Reference ID: 325852</citation>
  </reference>
  <reference>
    <citation>Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.</citation>
    <PMID>20212249</PMID>
  </reference>
  <reference>
    <citation>Ratts R, Trujillo C, Bharti A, vanderSpek J, Harrison R, Murphy JR. A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15635-40. Epub 2005 Oct 17.</citation>
    <PMID>16230620</PMID>
  </reference>
  <reference>
    <citation>Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9.</citation>
    <PMID>24421329</PMID>
  </reference>
  <reference>
    <citation>Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.</citation>
    <PMID>24007748</PMID>
  </reference>
  <reference>
    <citation>Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, Schlegelberger B, Johansson B, Hellström-Lindberg E, List A, Nilsson L, Jacobsen SE. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 2010 Sep 9;363(11):1025-37. doi: 10.1056/NEJMoa0912228.</citation>
    <PMID>20825315</PMID>
  </reference>
  <reference>
    <citation>Thorburn A, Thorburn J, Frankel AE. Induction of apoptosis by tumor cell-targeted toxins. Apoptosis. 2004 Jan;9(1):19-25. Review.</citation>
    <PMID>14739595</PMID>
  </reference>
  <reference>
    <citation>van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005 Sep 15;11(18):6520-7.</citation>
    <PMID>16166428</PMID>
  </reference>
  <reference>
    <citation>Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, Bardet V. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011 Dec;96(12):1792-8. doi: 10.3324/haematol.2011.047894. Epub 2011 Sep 20.</citation>
    <PMID>21933861</PMID>
  </reference>
  <reference>
    <citation>Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978 Sep;15(1):245-50.</citation>
    <PMID>699044</PMID>
  </reference>
  <reference>
    <citation>Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008 Jan 1;14(1):123-9. doi: 10.1158/1078-0432.CCR-07-0932.</citation>
    <PMID>18172261</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

